



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/587,049	06/02/2000	KAZUHIKO AMANO	P2292.D1	6603

20178 7590 02/25/2003

EPSON RESEARCH AND DEVELOPMENT INC
INTELLECTUAL PROPERTY DEPT
150 RIVER OAKS PARKWAY, SUITE 225
SAN JOSE, CA 95134

EXAMINER

NASSER, ROBERT L

ART UNIT	PAPER NUMBER
----------	--------------

3736

DATE MAILED: 02/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete each task.

4. The fourth step is to implement the plan. This involves putting the strategy into action and monitoring progress regularly to ensure that the project is on track.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes with the objectives and goals to determine the effectiveness of the project and identify areas for improvement.

Part of Paper No. 14

Art Unit: 3736

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Claims 2, 32, and 33 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Cosgrove Jr. et al, see column 5, lines 1-13, discussing using a combination of EEG and blood pressure to trigger administration of drugs.

Claims 13, 14, 16, 17, 25, 41, and 42 are rejected under 35 U.S.C. 102(e) as being anticipated by Amano et al 5,730,137 (Amano et al US). Amano shows a device that has a sensor to detect blood pressure or heart rate, a memory to store the blood pressure or heart rate signals, control means to determine when to administer a drug based on the rhythm of the blood pressure or heart rate, and a drug administration means, which is an infuser, to administer the drug.

Claims 13, 14, 16, 17, 25, 41, and 42 are rejected under 35 U.S.C. 102(e) as being anticipated by Amano et al Japanese document 7-148253 (Amano et al JP). This is the priority document to Amano 5,730,137.. Amano shows a device that has a sensor to detect blood pressure or heart rate, a memory to store the blood pressure or heart rate signals, control means

Art Unit: 3736

to determine when to administer a drug based on the rhythm of the blood pressure or heart rate, and a drug administration means, which is an infuser, to administer the drug.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 3, 4, and 35-38 are rejected under 35 U.S.C. 103(a) as being obvious over McNally et al. McNally teaches a system that has a sensor to monitor a parameter indicative of arousal or sedation (blood pressure) and produce a signal, means to processing the signal to control a drug delivery device to deliver a drug to the patient, by comparing the current signal with a stored parameter indicative of the desired state and either sedate the patient when the signal indicates arousal or arouse the patient when the signal indicates sedation. The drug delivery device is an infuser. The examiner notes that McNally administers two separate drugs, hypotensive and hypertensive agents. Whether one device controls both drugs, or each has a separate control would have been obvious to one skilled in the art.

Claims 5 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over McNally et al in view of Samiotes et al. Samiotes teaches not allowing drug delivery until a predetermined

Art Unit: 3736

time has passed since the last drug delivery to prevent overdosing of the patient. Hence, it would have been obvious to include such a monitor in McNally to prevent patient injury.

Claims 6-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over McNally et al in view of Sherer. Sherer further teaches recording the time of drug delivery, type of drug delivered etc to provide the physician with a complete record of the treatment. Hence, it would have been obvious to modify the McNally to use such a storage means, to keep the patient's treatment record up to date.

Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Amano et al in view of Falcone et al 5,464,012. Falcone further teaches that large changes from a running average value of a parameter are also a cause for concern and must be treated. Hence, it would have been obvious to modify Amano to respond to big changes b infusing drugs, to keep the levels constant.

Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over Amano et al US in view of Valcke et al and/or Amano et al JP in view of Valcke. Valcke further teaches sounding an alarm when the total amount of the drug administered reaches a set amount, to prevent overdosing the patient. Hence, it would have been obvious to modify Amano et al to include such an alarm , to prevent injury to the patient.

Claims 22-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Amano et al US and/or JP in view of Valcke et al as applied to claim 21 above, and further in view of Coutre et al. Coutre et al further teaches s monitoring the operating condition of a drug infusion system

Art Unit: 3736

and sounding alarms when the system is not operating correctly. Hence, it would have been obvious to modify Amano et al to use such a system monitor, to ensure proper system operation and proper patient treatment.

Claim 31 is rejected under 35 U.S.C. 103(a) as being unpatentable over Cosgrove jr. in view of Samiotes et al. Samiotes teaches not allowing drug delivery until a predetermined time has passed since the last drug delivery to prevent overdosing of the patient. Hence, it would have been obvious to include such a monitor in Cosgrove Jr. to prevent patient injury.

Claims 9-12, 39, and 40 are allowable.

Claims 15, 18, and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Applicant's arguments filed 11/26/2002 have been fully considered but they are not persuasive.

Applicant has argued that inventor Kodama in the Amano patent and inventor Uebaba in the present case are the same person and therefore the inventorship is the same. It is the examiner's position that mere attorney argument is insufficient to establish this fact and that the argument must be presented in affidavit form.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert L. Nasser Jr. whose telephone number is (703) 308-3251. The examiner can normally be reached on Monday-Thursday and alternate Fridays from 8:30 to 6:00.

Art Unit: 3736


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg, can be reached on (703) 308-3130. The fax phone number for this Group is (703) 308-0758.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [max.hindenburg@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0858.

RLN
February 19, 2003


ROBERT L. NASSER
PRIMARY EXAMINER